Obermatt
See Similar Stocks →

Flags

Financial distress

Cresco Labs

CNX:CL · CA22587M1068
PharmaceuticalsMedium

360

43
EV / EBIT52
Price / Owner Earnings56
Owner Earnings Yield1
Dividend Yield1
Price/Sales88
EV / Gross Profit60
Price/Book57
Return on Capital79
Cash Return on Capital36
Return on Equity28
EBIT Margin79
Gross Profitability61
Accruals80
Owner Earnings Margin33
Sales growth25
Profit Growth43
Long-Term EPS Growth30
Reinvestment43
Price momentum65
Debt load19
Refinancing92
Debt Payback1
Liquidity60
Analyst ratings84
Opinion Changes50
Price Target Upside83
Market mood40
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cresco Labs doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeCNSX
Employees937
Websitecrescolabs.com
ISINCA22587M1068
Last UpdateApr 2, 2026
Indices
Sound Pay Practices (USA)
Themes
CannabisAlternative MedicineHealth CareMedicalPharmaceutical

Description

Cresco Labs Inc. (‘Cresco’) operates as a vertically-integrated multi-state cannabis operators in the U.S. The company is licensed to cultivate, manufacture, and sell retail and medical cannabis products both through Sunnyside*, Cresco Labs’ nationa…

Analysis

Middle-of-the-road

Cresco Labs Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is fragile. The company scores 4/20 on our value-creation score: not creating value. Analysts lean positive.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
91
2023202420252026

All-time high

91

Jun 2026

All-time low

1

Jan 2025

Average rank

36

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
88
26
86
68
Price/Earnings
83
1
65
25
Price/Book
57
63
65
40
Dividend Yield
1
1
1
1
Value (overall)
92
32
74
35

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cresco Labs with its peers
Curaleaf Holdings
TOR:CURA
14
CountryUSA
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Cronos Group
TOR:CRON
45
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
High Tide
CVE:HITI
62
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
OrganiGram Holdings
TOR:OGI
39
CountryCanada
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Green Thumb Industries
CNX:GTII
79
CountryUSA
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Definium Therapeutics
NSQ:DFTX
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →